InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

Original reporting
Published Nov 13, 2026, 8:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 8:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
InspireMD (NSPR) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$NSPRBullishHigh
01

Why it matters

The approval expands the addressable market by ~40,000 procedures annually, potentially doubling revenue opportunity and supporting a strategic shift to commercial execution.

02

Market read

First‑time FDA approval for a micro‑cap med‑tech firm is a high‑impact catalyst likely to move the stock and influence sector peers.

03

What to watch

Potential supply chain constraints and the pending recall of the prior delivery system may limit near‑term sales

Relevance 8/10Novelty 8/10Timing: immediate, today

Background

InspireMD announced FDA clearance for its next‑generation CGuard Prime TransCarotid Stent, marking a return to the U.S. market after a prior recall.

Company-level read

Ticker impact

$NSPRBullishHigh confidence
Context

FDA approval of the CGuard Prime TransCarotid Stent System enables U.S. market entry and expands addressable procedures.

Expected impact

likely upward pressure as investors price in new U.S. sales potential

Evidence & confidence

Regulatory clearance is a material catalyst for a micro‑cap medical device firm, historically moving the stock sharply on first‑time approvals.

Market effects

strengthens outlook for carotid intervention devices and may benefit peers with similar pipelines

U.S. market re‑entry could boost domestic medical‑device sector sentiment

shows continued pipeline success for U.S. regulatory approvals in the global med‑tech space

Counterpoint

If commercial rollout stalls or reimbursement issues arise, the stock could face disappointment despite approval

Key entities

  • InspireMD

    Medical device maker focused on carotid revascularization

  • Kathy Kennedy

    Senior Vice President of Global Sales and Marketing

Related articles

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR

$NSPRMed

InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.